Vol. 7, Issue 2, Part I (2025)

Asthma is a chronic inflammatory airway disease characterized by reversible airflow obstruction, bronchial hyperresponsiveness, and episodic exacerbations. Achieving optimal control requires addressing both acute bronchoconstriction and persistent airway inflammation. This review focuses on the therapeutic importance of the Levosalbutamol-Beclomethasone dipropionate combination as an effective double drug strategy for asthma management. Levosalbutamol, an enantiomerically pure and highly selective short-acting β2-agonist (SABA), provides rapid bronchodilation with fewer β2-mediated adverse effects compared to racemic salbutamol. Beclomethasone dipropionate, a widely used inhaled corticosteroid (ICS), delivers potent local anti-inflammatory action, reducing airway edema, mucus production, and the frequency of exacerbations. Together, these agents offer a complementary mechanism: Levosalbutamol immediately relieves bronchospasm, while Beclomethasone dipropionate provides sustained control of underlying inflammation.

The concurrent or fixed-dose use of this combination is particularly beneficial for patients with mild to moderate persistent asthma who require both fast symptomatic relief and long-term control. Clinical evidence indicates improved peak expiratory flow, reduced nocturnal symptoms, and decreased reliance on rescue medication compared to monotherapy. This combination also fits well within stepwise asthma management guidelines, where ICS-SABA double therapy is recommended for individuals who remain uncontrolled with single-agent treatment. Despite established efficacy, barriers such as inconsistent adherence, incorrect inhaler technique, and variable individual response continue to influence treatment outcomes. Enhancing patient education, refining inhaler technologies, and tailoring therapy to individual phenotypes may improve overall effectiveness.